Plebanek, M., DeVito, N., Liu, F., Theivanthiran, B., Beasley, G., & Hanks, B. (2021). 657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway. In Regular and Young Investigator Award Abstracts (pp. A685–A685). BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2021-sitc2021.657

Plebanek, Michael, Nicholas DeVito, Fang Liu, Balamayooran Theivanthiran, Georgia Beasley, and Brent Hanks. “657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway.” In Regular and Young Investigator Award Abstracts, A685–A685. BMJ Publishing Group Ltd, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.657.

Plebanek M, DeVito N, Liu F, Theivanthiran B, Beasley G, Hanks B. 657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway. In: Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2021. p. A685–A685.

Plebanek, Michael, et al. “657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2021, pp. A685–A685. Crossref, doi:10.1136/jitc-2021-sitc2021.657.

Plebanek M, DeVito N, Liu F, Theivanthiran B, Beasley G, Hanks B. 657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway. Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2021. p. A685–A685.